Latest revenue
$823.4M
as of 2026-03-31
Latest net income
$14.4M
as of 2026-03-31
Net margin
1.7%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $51.96B
- Enterprise value
- $51.96B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 3.4%
- 52-wk high
- $419.83
- 52-wk low
- $253.58
- Beta
- —
- Shares out
- 151.7M
5-year trend
What this company does
ITEM 1 BUSINESS Our Business We are a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels. Many of our products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. Our products and solutions address the rapidly evolving needs of a diverse array of customers in life and materials science research, biopharmaceuticals, applied markets, microbiology, in-vitro diagnostics, and nanotechnology. Our technology platforms include magnetic resonance, mass…
AI summary unavailable — showing raw filing excerpt
Generated from BRKRP's filing dated 2026-02-27
Key risks
ITEM 1A RISK FACTORS The following risk factors should be considered in conjunction with the other information included in this Annual Report on Form 10-K, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our audited consolidated financial statements and related notes. This report may include forward-looking statements that involve risks and uncertainties. In addition to those risk factors discussed elsewhere in this report, we identify the following risk factors, which could affect our actual results and cause actual results to differ materially from those in the forward-looking statements. Risk Factor Summary Our business is subject to…
AI summary unavailable — showing raw filing excerpt
Generated from BRKRP's filing dated 2026-02-27
Profitability
Gross margin
45.9%
6.3%Operating margin
2.0%
73.6%Net margin
-0.3%
107.4%Return on equity
-0.4%
105.5%Return on assets
-0.1%
107.1%Leverage
Debt / equity
1.54×
31.8%Long-term debt / equity
0.75×
34.9%Debt / assets
60.6%
12.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $823.4M | +2.7% | $14.4M | -17.2% | 1.7% |
Q4 2025 2025-12-31 | $977.2M | -0.2% | $1.0M | -92.7% | 0.1% |
Q3 2025 2025-09-30 | $860.5M | -0.5% | $-34.6M | -184.6% | -4.0% |
Q2 2025 2025-06-30 | $797.4M | -0.4% | $7.6M | 0.0% | 1.0% |
Q1 2025 2025-03-31 | $801.4M | +11.0% | $17.4M | -65.8% | 2.2% |
Q4 2024 2024-12-31 | $979.6M | — | $13.7M | — | 1.4% |
Q3 2024 2024-09-30 | $864.4M | +16.4% | $40.9M | -53.6% | 4.7% |
Q2 2024 2024-06-30 | $800.7M | +17.4% | $7.6M | -86.7% | 0.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Laboratory Analytical Instruments · SIC 3826
Your notes
Keep private notes on BRKRP — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for BRKRP in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns BRKRP
Institutional value
$250.0M
Total shares held
881.5K
Distinct holders
14
-20 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | FRANKLIN RESOURCES INC | 200.0K | $56.5M | +0 (+0.0%) | No change |
| 2 | BlackRock, Inc. | 190.8K | $53.9M | -20.1K (-9.5%) | Trimmed |
| 3 | Calamos Advisors LLC | 142.0K | $40.1M | +343 (+0.2%) | Added |
| 4 | WOLVERINE ASSET MANAGEMENT LLC | 127.8K | $36.8M | +10.9K (+9.3%) | Added |
| 5 | ADVENT CAPITAL MANAGEMENT /DE/ | 71.1K | $20.6M | -15.6K (-18.0%) | Trimmed |
| 6 | Context Capital Management, LLC | 50.0K | $14.1M | +0 (+0.0%) | No change |
| 7 | JANE STREET GROUP, LLC | 38.3K | $10.8M | +1.4K (+3.8%) | Added |
| 8 | Walleye Capital LLC | 20.0K | $5.6M | +10.0K (+100.0%) | Added |
| 9 | JPMORGAN CHASE & CO | 16.5K | $4.6M | +15.8K (+2253.8%) | Added |
| 10 | Skaana Management L.P. | 9.9K | $2.8M | — | New |
| 11 | Invesco Ltd. | 10.0K | $2.8M | -5.0K (-33.3%) | Trimmed |
| 12 | AGF MANAGEMENT LTD | 3.0K | $846.8K | +2.0K (+200.0%) | Added |
| 13 | Elequin Capital, LP | 1.1K | $302.5K | +1.1K (+1234.9%) | Added |
| 14 | UBS Group AG | 1.0K | $286.5K | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once BRKRP's latest filing finishes processing.